The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations
- 3 July 2014
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 3 (7) , e946367
Abstract
Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.Keywords
This publication has 10 references indexed in Scilit:
- Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatmentExpert Review of Clinical Immunology, 2014
- Immune Checkpoint BlockadeHematology/Oncology Clinics of North America, 2014
- MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic CellsCancer Immunology Research, 2014
- Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanomaCancer, 2014
- Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanomaAnnals of Oncology, 2014
- Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF InhibitorCancer Immunology Research, 2014
- BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 InhibitionJournal of Clinical Oncology, 2013
- Tumor adaptation and resistance to RAF inhibitorsNature Medicine, 2013
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 2013
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 2013